Skip to main content

Table 2 Effects of chronic uremia and enalapril treatment on body weight, blood pressure, blood hemoglobin, plasma indices of uremia, plasma cholesterol, and aortic atherosclerosis in Study 2.

From: ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model

Study 2

  

Sham operation

(0 NX)

5/6 NX

 
   

No enalapril

Enalapril

 

Variable

Unit

(n = 7)

(n = 8)

(n = 13)

P

Body weight

g

32.1 ± 2.0

27.3 ± 2.1a

27.4 ± 2.0

< 0.001

Systolic blood pressure

mmHg

112.9 ± 6.1

116.8 ± 4.6

105.2 ± 7.2b

< 0.005

B-hemoglobin

mmol/L

9.60 ± 0.83

7.31 ± 0.97a

6.99 ± 0.66

< 0.001

P-urea

mmol/L

11.9 ± 1.1

28.6 ± 5.4a

26.3 ± 6.2

< 0.001

P-creatinine

mmol/L

0.016 ± 0.002

0.030 ± 0.007a

0.025 ± 0.006

< 0.001

P-phosphate

mmol/L

2.47 ± 0.47

2.78 ± 0.65

2.54 ± 0.39

NS

P-calcium

mmol/L

2.70 ± 0.21

2.95 ± 0.41

2.61 ± 0.07

< 0.05

P-Ca × P

mmol2/L2

6.65 ± 1.45

8.40 ± 3.19

6.63 ± 0.99

NS

P-cholesterol

mmol/L

16.3 ± 2.4

16.6 ± 3.3

13.5 ± 2.9b

< 0.05

Aortic plaque area fraction

%

0.10 ± 0.07

0.23 ± 0.08a

0.11 ± 0.04b

< 0.005

  1. Fasting blood samples obtained at the end of the study, i.e. when the animals were 46 weeks of age. Aortic plaque area fraction was determined by the en face technique. Enalapril was administered for 32 weeks with a dose of 2 mg/kg/d starting 4 weeks after the 5/6 nephrectomy. Values are mean ± SD. P-values were calculated using the Kruskal-Wallis test for differences between three groups. Two-group comparisons were performed using the t-test. Statistically significant difference vs. "Sham operation" group is denoted by superscript a. Statistically significant difference vs. "5/6 NX, No enalapril" group is denoted by superscript b.